Flortaucipir Imaging for Lewy Body Disease

Recruiting in Palo Alto (17 mi)

+1 other location

Overseen byKejal Kantarci, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: Kejal Kantarci

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The Researchers are trying to determine the paths of change in imaging biomarkers of Dementia with Lewy bodies (DLB) and their associations with rate of cognitive and functional decline.

Eligibility Criteria

This trial is for adults over 18 with probable Dementia with Lewy bodies (DLB). Participants need an informant who checks on them weekly, must speak English well, consent to the study's protocol, and be able to attend up to six visits over five years. They should not have other neurological disorders like multiple sclerosis or brain tumors that could affect results.

Inclusion Criteria

Reliable informant who personally speaks with or sees the participant at least weekly

At least 18 years of age

Sufficiently fluent in English

See 4 more

Exclusion Criteria

Unwilling to return for follow-up yearly and undergo neuropsychological testing and MR imaging

Do not have a reliable informant

You have another neurological disorder, like multiple sclerosis or a brain tumor, that could affect the study results.

See 1 more

Treatment Details

Interventions

18F-Flortaucipir (Radiopharmaceutical)

Trial OverviewThe study aims to track changes in imaging biomarkers related to DLB using a technique called 18F-Flortaucipir PET scanning. It will explore how these changes correlate with cognitive and functional decline in participants over time.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Dementia with Lewy BodiesExperimental Treatment1 Intervention

18F-Flortaucipir and 11C-Pittsburgh compound-B radioligands will be used for experimental PET imaging of beta-amyloid and neurofibrillary tau pathology